Lilly grants $4.2M for TB drug discovery; Chelsea gets priority review for Northera;

 @FierceBiotech: FDA delays review of key Takeda diabetes drug and Actos combo. Item | Follow @FierceBiotech

 @MaureenFierce: Sad: U.S. seniors having to pay more for their Rx drugs, according to a new study. Story | Follow @MaureenFierce

 @MarkHFierce: So Russia plans to be a global device competitor by 2020? Hmmm... Release | Follow @MarkHFierce

> Allocure has revealed some upbeat data from a Phase I study of its stem-cell therapy for acute kidney injury. Article

> The FDA has given Tonix Pharmaceuticals ($TNXP) the green light to go forward with trials of its drug TNX-102 for treating fibromyalgia. Release

> Chelsea Therapeutics ($CHTP) has garnered a priority review for its experimental hypertension drug Northera. Report

> Former AstraZeneca employees in the U.K. whose jobs were axed by the drug giant have set up their own life sciences shops. Item

> Alnylam Pharmaceuticals ($ALNY) has granted a non-exclusive license to its RNA-interference platform to Spanish biotech Sylentis to work on a synthetic siRNA drug for treating glaucoma. Release

> Eli Lilly ($LLY) has awarded a $4.2 million grant to the Infectious Disease Research Institute in Seattle to fund early work on hunting for drugs against tuberculosis. Article

Pharma News

 @FiercePharma: Counterfeiting tricks emerge in Chinese crackdown. E.g., to make fake little blue pills blue, add printer ink. News | Follow@FiercePharma

> Sandoz settles pricing suits with Florida, California. Report

> Eisai to hawk Novartis meds, while Shionogi sells for Shire. Article

> Pfizer, J&J among lawmakers' fave drug stocks. Item

> FDA pulls Avastin's breast cancer approval. Report

> EU watchdogs: Pradaxa risk can be managed. News

> Pfizer exec: Indian price move would push pharma to 'semi-recession.' Report

And Finally... Do you want to load up on tryptophan on Thanksgiving? You'll find more of it in roasted chicken than turkey. Item